Feature PureTech targeting dysfunctions in brain, gut, immune system By Len Zehr With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious... July 18, 2017